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Abstract
Introduction: Approximately one-third of adults in the United States have hyperten-
sion (HTN), leading to increased morbidity and mortality.
Objectives: This quality improvement intervention was designed to improve HTN
control among community-dwelling adults through collaboration between patient-
centered medical homes (PCMH) within an academic medical center and chain com-
munity pharmacies.
Methods: Four PCMH sites in Ann Arbor, Michigan that were in close proximity to
two Meijer pharmacies participated in this study between September 2016 and
March 2017, which compared HTN outcomes for patients seen at two community
pharmacies where the pharmacists received training on HTN management for
patients who received usual care at their PCMH. The primary outcome was percent
of patients who met their blood pressure (BP) goal of either <140/90 mmHg
or < 150/90 mmHg compared with matched controls who received usual care at the
PCMH. Secondary outcomes included number of medication recommendations made,
percent of recommendations accepted by the primary care provider (PCP), and
patient satisfaction.
Results: Patients who received care at the community pharmacy (n = 155) had a
higher rate of BP control at 3 months than matched controls (61.8% vs 47.7%,
P = 0.013). A total of 29 medication recommendations were made by community
pharmacists and 26 were accepted by the PCP. Nearly 95% of patients rated the care
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they received as excellent or very good and over 95% stated that they would recom-
mend the pharmacist at the Meijer pharmacy to their family and friends.
Conclusion: Patients who received HTN management services as part of a collabora-
tion between an academic medical center and chain community pharmacy were sig-
nificantly more likely to have controlled BP at 3 months compared with matched
controls who received standard care. This model shows promise as being a strategy
to expand access to care for patients while being mutually beneficial for community
pharmacies and health systems.
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1 | INTRODUCTION
Approximately one-third of adults in the United States have hyperten-
sion (HTN), leading to increased morbidity and mortality, particularly
from cardiovascular and kidney diseases.1 It is estimated that HTN is
the primary or contributing cause in 362 000 deaths and it leads to
nearly 39 million physician office visits annually.2-4 Pharmacologic and
nonpharmacologic treatment strategies exist to lower the burden of
elevated blood pressure (BP). In the general population in the United
States, 17.3% of people with HTN are unaware of their diagnosis and
therefore remain untreated.1 Furthermore, 48.2% of adults with diag-
nosed HTN continue to have uncontrolled BP and 37% of people do
not take their prescribed antihypertensive medications.1,5 Health sys-
tem leaders at Michigan Medicine (MM), an academic medical center,
reviewed Healthcare Effectiveness Data and Information Set (HEDIS)
measures and identified that metrics were not being met related to
BP management for adults and were charged with developing strate-
gies to improve the process for identifying, treating, and
monitoring BP.
A previous study implemented the use of a multidisciplinary team
consisting of medical assistants, clerical staff, physicians, and an
ambulatory care clinical pharmacist to improve BP control among
community-dwelling adults.6 Process changes included visual and
action-oriented high BP prompts, a collaborative practice agreement,
medication intensification protocol, and a home BP monitoring
machine loan program. These changes increased the percent of
patients meeting BP targets from 53.6% to 69.3% (P < .001).6
While ambulatory care-based pharmacists provide important clini-
cal services, the pharmacist that patients interact with frequently
resides in the community setting. Nearly 90% of Americans live within
5 miles of a community pharmacy, making the community pharmacist
the most accessible health care professional.7-9 This creates an oppor-
tunity for pharmacists to serve as an access point for patients to
receive primary care services in the community. Providing non-
dispensing services at a community pharmacy can increase accessibil-
ity for patients by being more convenient than a physician's office and
providing opportunities for evening and weekend visits.
Evidence is increasing about the positive impact of community
pharmacists on BP management. The Asheville Project demonstrated
sustained improvement in BP as a result of community pharmacist
education and long-term medication therapy management services.10
A randomized trial of 723 patients conducted in 56 community phar-
macies in Alberta demonstrated a significant reduction in risk for car-
diovascular events, including as a result of systolic BP reduction.11
Community pharmacist interventions focused on education, medica-
tion management, and lifestyle advice have been associated with a
significant reduction in systolic and diastolic BP.12 A pilot study dem-
onstrated that community pharmacists trained in PCMH clinics were
as effective at managing HTN as ambulatory care pharmacists at the
PCMH.13
2 | OBJECTIVE
The objective of this study was to improve rates of HTN control
among community-dwelling adults through collaboration between
patient-centered medical homes (PCMH) within an academic medical
center and chain community pharmacy.
3 | METHODS
3.1 | Setting
A total of four PCMH sites associated within an academic medical
center in Ann Arbor, Michigan that were within close proximity to
Meijer pharmacies participated in this study between September
2016 and March 2017. Initially, two PCMH sites were selected to
pilot the model and two additional sites were added in February
2017. A total of 16 hours of appointments were available per week
between the two Meijer pharmacies. The pharmacies filled approxi-
mately 2250 and 2850 prescriptions weekly.
MM paid Meijer pharmacy for HTN management services as
improving uncontrolled BP had been selected as a priority for the
organization. Based on an agreement, Meijer sent an invoice to MM
and was compensated by hours per week, regardless of whether there
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were appointments scheduled or completed. The contracted rate was
based on the cost of a pharmacist without advanced training. Meijer
pharmacy paid for the pharmacists' time to complete the training and
continued to pay for pharmacist benefits. Pharmacists did not partici-
pate in the pharmacy workflow during clinic hours; however, they par-
ticipated in dispensing and nondispensing services before and after
the HTN clinic.
3.2 | Community pharmacist participation and
training
Community pharmacists employed at a Meijer pharmacy located at or
near a participating location and interested in providing HTN manage-
ment services were eligible for the position. Interested candidates
(n = 5) were interviewed by the Meijer pharmacy district manager.
Most pharmacists (n = 4) had a Doctor of Pharmacy degree The phar-
macy district manager playing the role of a patient to assess the phar-
macist's HTN management knowledge and motivational interviewing
skills. All five pharmacists were trained with the intent that two phar-
macists would be dedicated to each Meijer pharmacy plus one addi-
tional pharmacist who could provide coverage at both pharmacies, as
needed. The district manager who is a licensed pharmacist also com-
pleted the training in order to be familiar with the roles and responsi-
bilities of her direct reports.
The district manager referred the pharmacists to the MM Adminis-
trative Lead who was responsible for obtaining the curriculum vitaes
of the pharmacists and ensuring their licensure with the state
(Table A1). The Administrative Lead was the primary point of contact
between the pharmacists and MM and oversaw the steps necessary
for pharmacists to gain access to the electronic health record (EHR) as
well as the nonclinical aspects of training. Pharmacists were required
to complete 12 hours of live training regarding how to use the EHR.
The Meijer pharmacists were also supervised by a Clinical Lead
who is an ambulatory care pharmacist experienced in HTN manage-
ment. The Clinical Lead was responsible for providing training regard-
ing HTN management according to the established policies at MM
and teaching the pharmacists how to gather and document pertinent
information in the EHR. There was approximately 12 hours of clinical
training, divided in 3-4 hour weekly sessions.
Pharmacist competence was assessed via multiple choice tests
and a review of their documentation and recommendations by the
Clinical Lead. At the beginning of training, pharmacists completed a
10-question multiple choice assessment regarding which section of
the Subjective, Objective, Assessment, and Plan (SOAP) note to docu-
ment specific information as well as a 10-question multiple choice
assessment regarding clinical and protocol competency. After training
was completed and the pharmacist began to provide patient care ser-
vices, they initially sent their recommendations to the Clinical Lead
who helped to building relationships between the physicians and the
Meijer pharmacists. After the Clinical Lead agreed with at least 80%
of their recommendations and the pharmacist retook the two multiple
choice assessments and scored 100% on each, they were allowed to
send recommendations directly to the primary care provider (PCP)
(Table A2).
The health system developed a policy to ensure that all commu-
nity pharmacists who provided contracted services were supervised
by designated MM physicians. One hour bi-monthly videoconferences
between the community pharmacists, Clinical Lead, Administrative
Lead, and a medical director were held in order to discuss patient
cases, review records for completeness and accuracy, review MM
guidelines, and discuss new information in the area of HTN manage-
ment. Two medical directors alternated participation in this meeting.
3.3 | Intervention
A protocol was developed to systematically identify patients with high
BP and refer them for follow-up at either their PCMH or Meijer phar-
macy (Figure 1). All adults had a BP reading obtained by a medical
assistant (MA) as part of the routine intake process when they pres-
ented for an appointment at a participating PCMH. If the BP was ele-
vated, the MA rechecked it after at least 5 minutes and if an abnormal
reading persisted, the MA attached a standing order for a referral to a
pharmacist for BP follow-up in the EHR. If the PCP signed the order,
the check-out staff were instructed to schedule the visit. During the
first 15 weeks of the intervention, the Administrative Lead also
reached out to eligible patients based on recent clinic visit notes in
order to build the patient population in the newly created Meijer BP
clinics, while helping patients who recently had elevated BP with no
follow-up scheduled. This was done as it was anticipated that it would
take several weeks for the appointment slots to be filled through
referrals from the new program and it was important to give commu-
nity pharmacists the opportunity to apply the knowledge and skills
they had recently developed.
Patients were given the option to follow-up either with a pharma-
cist at the PCMH or at a Meijer pharmacy within 2-4 weeks. Services
were the same at both locations. Check out staff were given a short
script about the partnership with Meijer pharmacy including hours of
operation for each pharmacy and clarification that there would be no
cost. Patients did not need to obtain medications from a Meijer phar-
macy in order to participate. Patients called the PCMH if they needed
to reschedule the appointment. A program phone number was also
created and shared with patients. Clinic staff were asked to call the
Administrative Lead if there were any questions regarding the
program.
A protocol was developed to standardize the BP visit at the com-
munity pharmacy (Table 1). This was based on existing HTN guidelines
Medical 
assistant 
identifies 
patient with 
elevated 
BP†
Medical 
assistant 
creates and 
pends a 
referral for a
pharmacist 
BP visit
Clinician 
reviews and 
signs the 
referral, if 
appropriate
patient is
At checkout, 
given option 
to follow up 
at PCMH or 
Meijer
pharmacy
Check out 
staff 
schedules 
pharmacist 
BP
appointment 
in MiChart
F IGURE 1 Patient identification and referral process at patient-
centered medical home (PCMH). BP, blood pressure. †Systolic blood
pressure ≥140 and/or diastolic blood pressure ≥90 mmHg
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at MM Upon arrival at a Meijer pharmacy, the patient was checked in
for their appointment via the EHR by the community pharmacist. All
appointments were scheduled for 30 minutes, with new patient
appointments generally requiring the full time and return visits typi-
cally lasting less than 30 minutes. The original structure allowed for
30 minutes in between each appointment for completing other tasks,
namely visit documentation in the EHR. However, the structure was
modified to instead give pharmacists 30 minutes before and after the
clinic shift due to the increased efficiency of the pharmacists to com-
plete visit documentation. It also allowed for a model that was more
scalable from the retail pharmacy perspective, as it lessens the time
that the pharmacist spends on documentation.
During the visit, the pharmacist gathered information from the
patient related to (1) their lifestyle, such as diet (including sodium and
caffeine intake), physical activity, smoking status, alcohol use, and
stress; (2) current and previous medication use, tolerability, cost con-
cerns, and adherence; (3) pertinent review of systems such as chest
pain, shortness of breath, edema, and pain; and (4) recent home BP
values. The patient's BP was collected using the BpTRU machine
(BpTRU Medical Devices, Coquitlam, BC, Canada), which is an auto-
mated oscillometric device that obtains six readings 1 to 5 minutes
apart, discards the first reading, and averages the remaining five read-
ings.14 This device was selected as it is more accurate than taking the
average of three manual BP readings in the office setting and as accu-
rate as 24 hours ambulatory BP monitoring (ABPM) or ABPM daytime
averages.15,16 BP was obtained manually if determined necessary by
the pharmacist or requested by the patient. During visits, pharmacists
validated home BP cuffs, worked with patients to set diet and physical
activity goals, made recommendations to either start, stop, or titrate
doses of antihypertensive medications up or down, and recommended
basic metabolic panels. Educational materials were handed out at the
discretion of the pharmacist.
Information about the visit, including recommendations regarding
proposed medication changes, were communicated to the PCP via a
standardized template in the EHR sent as high priority the same day
as the visit. If there was no acknowledgement within 72 business
hours, a second encounter with the same message was routed to the
PCP. Pharmacists subsequently called the clinic if there was no
response in 24-48 business hours of the second attempt in order to
make the medication recommendation to either the PCP or staff
member who had the ability to get in contact with the PCP the same
day. In the event that the PCP was still unable to be reached, the
pharmacist contacted the Meijer Program MM Clinical Lead who was
able to page the PCP. If the pharmacist received an automatic mes-
sage within the EHR indicating that the PCP was out of the office, the
Meijer pharmacist called the PCMH clinic and asked the nurse to tri-
age the message to the appropriate covering clinician.
The pharmacist scheduled a follow-up visit with the patient
between 2-4 weeks later, depending on whether the BP was con-
trolled or uncontrolled during the visit. If the patient's BP was con-
trolled for two consecutive visits, the patient was discharged back to
the PCP.
3.4 | Data collection and analysis
Patients who received BP management at a Meijer pharmacy (cases)
and the PCMH (controls) were matched on the basis of age, sex, and
BP goal. These criteria were selected based on the information that
was readily available about each patient. Any case (n = 2) who was
not able to be matched was excluded from the analysis comparing
systolic and diastolic BP. However, all cases were included in the
overall analysis to determine the percent of patients at goal. The per-
cent of patients meeting their BP goal was compared as opposed to
reduction in BP, as this aligns with how data is analyzed when looking
at HEDIS measures. BP goals were based on Eighth Joint National
Committee (JNC 8) Guidelines.17 The BP goal was less than
140/90 mmHg for patients less than 60 years old and those with dia-
betes mellitus or chronic kidney disease. The goal was less than
150/90 mmHg for patients 60 years or older without diabetes
mellitus or chronic kidney disease. The index visit BP, defined as the
BP recorded in the EHR at the PCP appointment, was compared with
the last BP recorded in the EHR at 3 months. If the patient did not
TABLE 1 Community pharmacist clinical protocol for blood
pressure monitoring
Systolic blood
pressure
(mmHg)
Diastolic
blood
pressure
(mmHg) Patient symptoms
Pharmacist
action
No symptoms
<159 <99 None Note via
in-basket
(high priority)
160-200 100-120
201 or higher 121 or
higher
Send to ED/call
911
Symptoms
Less than 100 Less than 60 Dizziness or
lightheadedness
Call clinic or
page PCP
140-159 60-99 Shortness of breath,
chest pain, severe
headache
160–200 100–120 Shortness of breath,
chest pain, severe
headache,
symptoms of
stroke,
encephalopathy
(nausea, vomiting,
changes in vision,
decreased
consciousness)
Send to
emergency
department
or call 911
201 or higher 121 or
higher
Regardless of
symptoms
Note: If the systolic and diastolic blood pressures fall into two different
categories, the pharmacist should take the action associated with the
higher category (eg, patient with no symptoms with a blood pressure of
182/122 mmHg - send to emergency department or call 911).
Abbreviations: ED, emergency department; PCP, primary care physician.
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have any follow-up appointments, the BP from the index visit was
used in the analysis as this aligns with how data is used when evaluat-
ing HEDIS measures. Process measures related to the Meijer phar-
macy program included number of referrals, scheduled and completed
visits, no show rate, number of medication changes recommended
and accepted by the PCP, and patient satisfaction. This study was
deemed not regulated by the Institutional Review Board of the Uni-
versity of Michigan Medical School (IRBMED).
Frequency distributions and descriptive statistics were used. Com-
parison of baseline and 3 months systolic and diastolic BP between
patients who received care at a Meijer pharmacy (cases) and PCMH
(controls) were compared using a t test. Rates of BP control were
compared using a χ2 test. Each patient was handed a paper survey to
complete at the end of their visit at a Meijer pharmacy. The 14-item
survey was developed based on an existing patient survey focused on
a different topic. Most questions used a three-point Likert scale (yes,
definitely; yes, somewhat; and no). The pharmacist left the room and
the patient was instructed to place their survey in a locked box upon
completion. An administrative assistant was the only person with
access to the box and would go to the stores once a month to gather
the surveys. Patient satisfaction surveys were collected on an ongoing
basis and analyzed for this manuscript through March 2017. Analysis
was conducted using Microsoft Excel 2016.
4 | RESULTS
A total of 200 referrals for BP management services were made dur-
ing the study period. A total of 33 patients (16.5%) were identified as
part of the central outreach process by the Administrative Lead and
the remaining referrals were made by the PCMHs. The median num-
ber of referrals was 2.6 per PCMH per week.
The majority of scheduled visits at Meijer pharmacies were for
new patient appointments (n = 205, 78.2%) and the remaining
appointments were for return visits (n = 57, 21.8%). The number of
new patient appointments scheduled exceeded the number of refer-
rals as patients who did not present for their new patient appointment
could schedule an additional new patient appointment. The majority
of referred patients (n = 157/200, 78.5%) completed their new patient
appointment. Over three-fourths of scheduled appointments were
completed (n = 203/262, 77.5%) with no statistically significant differ-
ence in the percentage of completed visits for new patient and return
visits (n = 157/205, 76.6% and n = 46/57, 80.7%, respectively). The
overall no show rate was 22.5% (n = 59/262).
A total of 155 of the 157 unique patients were matched with con-
trols. Baseline and 3 months systolic and diastolic BP was compared
(Table 2). At 3 months, 61.8% of cases met their BP goal compared
with 47.7% of controls (P = .013) (Table 3. One-half (n = 12/24) of the
medication recommendations for patients with uncontrolled BP were
to add a medication with the remaining recommendations to increase
the dose of an existing medication. Most medication recommenda-
tions that were made were accepted by the PCP (n = 26/29, 89.7%)
(Table 4). The most common reasons for not making a medication
recommendation when a patient had uncontrolled BP was because
the patient was focusing on lifestyle modifications (n = 27), adherence
issues were addressed (n = 16), or the BP was improving (n = 9). The
reason for medication recommendations during visits with controlled
BP included decreasing the dose for patient safety purposes (n = 2),
switching antihypertensive medications (n = 2), and changing the
timing of the administration to promote adherence (n = 1); all recom-
mendations were accepted by the PCP.
Patients who completed the survey (n = 169/203, 83.3%) were
highly satisfied with the care they received and would recommend
the pharmacist to their family and friends. The care provided was gen-
erally rated as excellent (n = 119/163, 73.0%) or very good
TABLE 2 Mean baseline and three-month systolic and diastolic
blood pressure among cases and controls
Time Controls (n = 155) Cases (n = 155) P value
Systolic blood pressure
Baseline 153.6 150.0 .029
Three months 142.0 136.5 .007
Diastolic blood pressure
Baseline 85.5 86.4 .400
Three months 80.5 79.0 .235
TABLE 3 Number and percent of patients reaching blood
pressure goal at 3 months
Time Controls n (%) Cases n (%) P value
At goal 74 (47.7) 97 (61.8) .013
Not at goal 81 (52.3) 60 (38.2)
TABLE 4 Medication changes among visits in which patients had
controlled or uncontrolled blood pressure
Uncontrolled
BP (n = 93)
Controlled
BP
(n = 108)
Total
(n = 201)
Number of medication
recommendations
made to PCP
24 5 29
Percentage of visits
with medication
recommendation
25.8 4.6 14.4
Medication
recommendations
accepted by PCP
21 5 26
Percentage of
medication
recommendations
accepted by PCP
87.5 100 89.7
Abbreviations: BP, blood pressure; PCP, primary care provider.
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(n = 41/163 25.2%). Examples of feedback that patients provided
included “I trust this pharmacist to help me achieve better health,”
“This was very convenient… The pharmacist was very knowledgeable
and I felt confident with the suggestions given,” and “The information
among with his friendly persona made me feel relaxed. I will take heed
to the information about improving my health.”
5 | DISCUSSION
Nearly 14% more patients who received HTN management services
at the community pharmacy met their BP goal compared with patients
receiving standard care at the PCMH. Medication recommendations
were generally accepted by the PCP. Patients reported being highly
satisfied with the service. This is significant as it has been proposed
that elimination of HTN could reduce death due to cardiovascular dis-
ease by 30% for men and 38% for women.18
Pharmacists are increasingly being recognized for their ability to
provide cost-effective HTN management that improves patient out-
comes.19-25 The optimal strategy for incorporating pharmacists con-
tinues to be studied; however, the necessity of team-based care has
been established and there is growing evidence that community phar-
macist integration is supported within PCMHs.26,27 Extending care
into the community allows patients to engage with high quality health
care services in a convenient setting. This may provide an opportunity
to address persistent HTN-related health disparities.
One of the key elements was to provide training to the commu-
nity pharmacists. The training model described in this study is more
feasible and offers increased opportunities for expansion compared
with the immersion program in which the community pharmacist is
trained at the PCMH.13 Access to the patient's full EHR by the com-
munity pharmacist was important to foster bi-directional communica-
tion between pharmacists and the referring physicians. Community
pharmacist access to the EHR continues to be sparsely reported in the
literature.28-30 Finally, dedicated time for scheduled patient appoint-
ments at the community pharmacy was crucial to the success of this
partnership.
The primary limitation to this study is that it represents the work
of one academic medical center in collaboration with one chain com-
munity pharmacy, and a small number of patients participated. Further
work is necessary to determine how to implement this intervention at
different institutions with varying organizational structures, opportu-
nities, and barriers. Secondly, the patient population may not repre-
sent the general population. Limited characteristic data was collected
from individuals and as a result it was not possible to describe the
patient population who benefited from this intervention. Additionally,
patients self-selected into the community pharmacy intervention and
therefore assigning patients to go to a community pharmacy may not
lead to the same results. Systolic BP was lower among controls; how-
ever, the average BP reduction was higher than the cases. The rate at
which PCPs signed the orders for HTN management services needs to
be studied. Furthermore, we did not study persistence of lifestyle
changes, BP medication adherence, and BP control after patients have
reached their BP goal and discontinued follow-up with the service.
Studying the sustainability of the clinical service model and explora-
tion about whether and how this program may address health dispar-
ities is necessary. Further evaluation of this program is underway in
collaboration with the Centers for Disease Control and Prevention to
address some of these limitations.31
6 | CONCLUSION
Patients who received HTN management services as part of a collabo-
ration between an academic medical center and chain community
pharmacy were significantly more likely to have controlled BP at
3 months compared with matched controls who received usual care
(61.8% vs 47.7%, P = .013). Nearly 95% of patients rated the care they
received as excellent or very good and over 95% stated that they
would recommend the pharmacist at the Meijer pharmacy to their
family and friends. This model shows promise as being a strategy to
expand access to care for patients while being mutually beneficial for
community pharmacies and health systems.
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TABLE A1 Community blood pressure center on-boarding
checklist
Administrative Lead Responsibilities
• Verify current pharmacist license
• Verification of Health Insurance Portability and Accountability Act
(HIPAA) training
• Obtain copy of curriculum vitae or resume
• Request MiChart (Epic) access
• Schedule ambulatory pharmacist MiChart training
• Schedule check in/check out training
• Provide training on BpTru device
• Provide training on marking patients as having arrived for their
visit in MiChart
Clinical Lead Responsibilities
Michigan Medicine hypertension guidelines, medications, and
management training
• Michigan Medicine hypertension protocol
• Michigan Medicine clinical hypertension guidelines
• Hypertension cases presentation
• Hypertension updates in guidelines presentation
• Community pharmacist blood pressure reading protocol
• Physician outreach procedure
• Managing delays in patient care
• Managing resistance/reluctance in patient care
MiChart ambulatory clinical pharmacist training
• Navigation training: labs, vitals, previous medications, notes
• Hypertension in-clinic encounter workflow
• Telephone encounter workflow
Ambulatory clinical pharmacist training
• Community blood pressure center workflow
• Clinical protocol competency
• SOAP note competency
• Documentation processes and standards in MiChart
• Manual blood pressure training
• Home blood pressure cuff validation
Abbreviation: SOAP, subjective, objective, assessment, and plan.
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TABLE A2 Community pharmacist competency evaluation
Item Description
Performance Evaluation (date/initial
each entry if met required item): Circle Y
for Yes, N for No
Self-Evaluation
Clinical Lead
Evaluation
Completed training prior to conducting Meijer
Pharmacy HTN visits
• Training checklist completed and initialed where
necessary by Michigan Medicine Clinical and
Administrative Leads
Y/N Y/N
Clinical Lead no longer sending extensivea weekly
emails regarding note documentation
improvement/feedback
• Segregation of information into appropriate
note sections - subjective, objective,
assessment, and plan (SOAP)
• Clarity of verbiage
• Following clinical/guideline protocols
Y/N Y/N
Clinical Lead no longer sending extensivea weekly
emails regarding patient care follow-up or
outstanding items
• Following physician outreach protocol
• Pending necessary recommended orders - basic
metabolic panel and medication
• Completing patient outreach
 Documented and time stamped telephone
call outreach notifying patient of medication
and/or lab recommendation
Y/N Y/N
Clinical Lead agrees with recentb medication/lab
recommendations ≥80% of the time (agrees
with last 4/5 recommendations)
• Medication choice and rationale
• Basic metabolic panel timing obtainment
Y/N Y/N
Competencies 100% score • Two competencies provided during training
(clinical protocol; SOAP note)
Y/N Y/N
Ongoing provider proficiency evaluation • Physician review of 2–3 patient case encounters
containing medication changes every 8 months
 Occur during bi-monthly videoconference
calls with medical directors
Y/N Y/N
Note: Pharmacists who meet competency standards described below are able to send recommendations directly to Primary Care Provider instead of
Clinical Lead for approval.
Abbreviation: HTN, hypertension.
aContaining more than three items.
bLast five.
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